首页> 外文期刊>Surgery Today >Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case
【24h】

Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case

机译:贝伐单抗联合紫杉醇治疗乳腺癌皮肤转移后伤口愈合不良和大溃疡扩张:一例报告

获取原文
获取原文并翻译 | 示例
           

摘要

A 48-year-old Japanese woman was found to have local recurrence of breast cancer in the chest wall following neoadjuvant chemotherapy, total mastectomy with axillary lymphadenectomy, postoperative radiation therapy to the chest wall, and adjuvant systemic therapy using trastuzumab. As a third line of treatment after recurrence, bevacizumab with paclitaxel was initiated for several metastatic lesions on the skin of the chest wall, left internal costal lymph nodes, and right axillary lymph nodes. The wound on the chest wall continued to expand in diameter and depth after the third course of bevacizumab with paclitaxel until the rib was exposed. After stopping the bevacizumab, granulation tissue expanded and by 3 months, had covered the bottom of the ulcer. The patient died soon thereafter, despite systemic chemotherapy with eribulin; however, there was no further bleeding from the ulcer on the chest wall or the exposed ribs.
机译:发现一名48岁的日本妇女在新辅助化疗,全乳切除加腋窝淋巴结清扫术,术后对胸壁进行放射治疗以及使用曲妥珠单抗进行全身辅助治疗后,在胸壁局部复发了乳腺癌。作为复发后的第三线治疗,贝伐单抗联合紫杉醇用于胸壁皮肤,左肋内侧淋巴结和右腋窝淋巴结的多个转移性病变。贝伐单抗联合紫杉醇治疗第三个疗程后,胸壁伤口的直径和深度继续扩大,直到肋骨暴露。停止使用贝伐单抗后,肉芽组织扩张,并在3个月前覆盖了溃疡的底部。此后不久,尽管接受了eribulin的全身化疗,但该患者死亡。但是,胸壁溃疡或暴露的肋骨没有进一步出血。

著录项

  • 来源
    《Surgery Today》 |2015年第4期|498-502|共5页
  • 作者单位

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

    Department of Digestive Surgery Breast and Thyroid Surgery Kagoshima University Graduate School of Medical and Dental Sciences">(1);

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Breast cancer; Recurrence; Bevacizumab; Wound healing; Skin metastasis; Chemotherapy;

    机译:乳腺癌;复发;贝伐单抗;伤口愈合;皮肤转移;化学疗法;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号